Company intelligence / Profile preview

RiverWalk Therapeutics

San Antonio, Texas, United Statesriverwalktherapeutics.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

RiverWalk's lead small molecules have demonstrated potencies to inhibit primary and metastatic tumors, stimulate anti-cancer immune response, reduce circulating tumor cells, and improve overall survival in mouse models of Triple Negative Breast Cancer[5]

Therapeutic areas
Oncology
Modalities
Small molecules
Industry
Biotech
02

Drug pipeline

1 asset

RiverWalk A2A/A2B receptor inhibitor

Preclinical

Beyond the preview

Go deeper on RiverWalk Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RiverWalk Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call